Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The FTY720 story.

K L Napoli1

  • 1Department of Surgery, The University of Texas Medical School at Houston, 77030, USA.

Therapeutic Drug Monitoring
|February 25, 2000
PubMed
Summary
This summary is machine-generated.

FTY720, a novel immunosuppressant, effectively reduces circulating lymphocytes by altering their trafficking patterns. Early clinical trials show safety and tolerability in renal transplant patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From beach to bedside: history of the development of sirolimus.

Therapeutic drug monitoring·2001
Same author

The development of sirolimus: The University of Texas-Houston experience.

Clinical transplants·2001
Same author

Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry.

Clinical biochemistry·2001
Same author

Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.

Transplantation·2001
Same author

Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes.

Transplantation proceedings·2001
Same author

Cytochrome P450 3A9 catalyzes the metabolism of progesterone and other steroid hormones.

Molecular and cellular biochemistry·2000

Area of Science:

  • Immunology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • FTY720 (2-amino-2[2-(4-octylphenyl)ethyl]-1,3,propane diol) is a synthetic small-molecule immunosuppressant.
  • It was developed to improve upon the in vivo toxicity profile of myriocin.
  • FTY720 exhibits a unique mechanism of action distinct from myriocin's inhibition of serine palmitoyl transferase.

Purpose of the Study:

  • To investigate the mechanism of action of FTY720.
  • To evaluate the efficacy and safety of FTY720 as an immunosuppressive agent.
  • To explore FTY720's potential in organ transplantation.

Main Methods:

  • Chemical synthesis of FTY720.
  • In vivo studies in animal models.
  • Phase 1 human clinical trials in renal transplant recipients.

Related Experiment Videos

Main Results:

  • FTY720 significantly reduces circulating lymphocyte counts.
  • Proposed mechanism involves modulation of lymphocyte trafficking via cell surface receptors.
  • Phase 1 trials demonstrated safety and tolerability in adult renal transplant recipients.

Conclusions:

  • FTY720 represents a novel class of immunosuppressants with a unique mechanism.
  • Its efficacy is demonstrated in preclinical models, particularly with cyclosporine combination therapy.
  • FTY720 shows promise as a future immunosuppressive therapy for organ transplantation.